The modified polypeptide can be combined with human albumin to enhance the resistance to DPP-4 and prolong the half-life to 5-6 days
Labeling update (2026): The FDA recently removed suicidal behavior and ideation language from the labeling of certain GLP-1 medicines used for chronic weight management, following a comprehensive safety review that found no evidence of increased risk
Thus, the reduction of GLP-1 expressing cells under inflammatory conditions in the intestine should also profoundly affect signaling of additional gut hormones
These conditions may amplify GLP-1 side effects, particularly during menstruation
In smaller acute metabolic studies with DPP-4 inhibitors, a reduction of the post-prandial rise in triglycerides, and apolipoprotein-B 48 was observed
Parab P, Chaudhary P, Mukhtar S, Moradi A, Kodali A, Okoye C, Klein D, Mohamoud I, Olanisa OO, Hamid P